ReproCELL Incorporated Logo

ReproCELL Incorporated

Offers stem cell tech, gene editing & drug discovery services for preclinical/clinical research.

4978 | T

Overview

Corporate Details

ISIN(s):
JP3974770004
LEI:
Country:
Japan
Address:
横浜市港北区新横浜3−8−11
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

ReproCELL Incorporated is a global life sciences company providing products and services for preclinical and clinical research, with a focus on stem cell technology, drug discovery, and regenerative medicine. Established in 2003 as a pioneer in the field, the company offers a comprehensive portfolio that supports the entire research workflow. Key offerings include induced pluripotent stem cell (iPSC)-derived human cells, such as neurons and cardiomyocytes, clinical gene editing services, cell culture reagents, and end-to-end discovery platforms for neuroscience and immuno-oncology. ReproCELL serves scientists and pharmaceutical companies worldwide, aiming to accelerate the translation of research into novel therapies and improve human health.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-13 07:35
Registration Form
確認書
Japanese 8.1 KB
2025-11-13 07:35
Interim Report
半期報告書-第24期(2025/04/01-2026/03/31)
Japanese 219.0 KB
2025-06-26 02:41
Regulatory News Service
内部統制報告書-第23期(2024/04/01-2025/03/31)
Japanese 23.4 KB
2025-06-26 02:41
Registration Form
確認書
Japanese 8.1 KB
2025-06-26 02:40
Annual Report
有価証券報告書-第23期(2024/04/01-2025/03/31)
Japanese 1.1 MB
2024-11-13 07:31
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-11-13 07:31
Interim Report
半期報告書-第23期(2024/04/01-2025/03/31)
Japanese 221.1 KB
2024-06-26 03:02
Post-Annual General Meeting Information
臨時報告書
Japanese 28.0 KB
2024-06-25 07:31
Governance Information
内部統制報告書-第22期(2023/04/01-2024/03/31)
Japanese 22.2 KB
2024-06-25 07:30
Registration Form
確認書
Japanese 8.2 KB
2024-06-25 07:29
Annual Report
有価証券報告書-第22期(2023/04/01-2024/03/31)
Japanese 1.2 MB
2024-05-23 08:02
Regulatory News Service
臨時報告書
Japanese 20.0 KB
2024-02-09 07:24
Report Publication Announcement
確認書
Japanese 8.2 KB
2024-02-09 07:23
Quarterly Report
四半期報告書-第22期第3四半期(2023/10/01-2023/12/31)
Japanese 227.6 KB
2023-11-10 07:05
Quarterly Report
四半期報告書-第22期第2四半期(2023/07/01-2023/09/30)
Japanese 213.2 KB

Automate Your Workflow. Get a real-time feed of all ReproCELL Incorporated filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ReproCELL Incorporated

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ReproCELL Incorporated via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

NRGene Technologies Ltd. Logo
AI-powered genomic analysis software to accelerate and optimize plant and animal breeding.
Israel
NRGN
Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America
OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150
Onconic Therapeutics Inc. Logo
Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.
South Korea
476060

Talk to a Data Expert

Have a question? We'll get back to you promptly.